ANDA sponsors feel some more tweaking of the assessment process is necessary to speed approval of complex generics, but the US Food and Drug Administration appears more willing to wait for the current process to bear fruit.
In what may be a rare case of indirectly open generic drug user fee reauthorization negotiating, generic sponsors suggested several...




